A case of ALK-rearranged non-small cell lung cancer that responded to ceritinib after development of resistance to alectinib
| Autor: | Masayuki Takeda, Yosuke Makuuchi, Junko Tanizaki, Kaoru Tanaka, Kazuhiko Nakagawa, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Shigeki Shimizu, Akihiko Ito, Koji Haratani |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Alectinib
non-small cell lung cancer (NSCLC) Case Report 03 medical and health sciences anaplastic lymphoma kinase (ALK) fusion gene 0302 clinical medicine hemic and lymphatic diseases non–small cell lung cancer (NSCLC) medicine ceritinib Anaplastic lymphoma kinase alectinib 030212 general & internal medicine Lung cancer Ceritinib Crizotinib business.industry Standard treatment medicine.disease respiratory tract diseases Oncology 030220 oncology & carcinogenesis Cancer research L1196M business Tyrosine kinase medicine.drug |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | The second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) alectinib and ceritinib are standard treatment options for patients with non–small cell lung cancer (NSCLC) positive for ALK fusion genes. However, almost all patients eventually develop resistance to these drugs. We here report a case of ALK-rearranged NSCLC that developed resistance to alectinib but remained sensitive to ceritinib. The L1196M mutation within the ALK fusion gene was detected after failure of consecutive treatment with crizotinib and alectinib, but no other mechanism underlying acquired resistance to ALK-TKIs was found to be operative. Given the increasing application of ALK-TKIs to the treatment of patients with ALK-rearranged NSCLC, further clinical evaluation is warranted to provide a better understanding of the mechanisms of acquired resistance to these agents and to inform treatment strategies for such tumors harboring secondary mutations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|